Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

Biogen's revenues declined 3% in the first nine months of 2024. Sales of Biogen’s key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Court cites lack of inventiveness and failure to meet reproducibility standards | Decision part of broader international ...

Some neurologists have even started talking about the possibility that the drugs could not only slow down progression of MS, but even potentially offer a functional cure. Biogen licensed rights to ...

There has also been a shift in treatment preferences over the years in MS towards B-cell depleting therapies like Roche's (OTCQX:RHHBY) Ocrevus (Biogen earned $346.8 million in Q3 from Ocrvus ...

Biogen’s top-line remains heavily reliant on its multiple sclerosis (MS) portfolio, which accounts for over 60% of 2024 revenue, including royalties from Ocrevus. Piper Sandler flagged several ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

Fifth Third Bancorp reduced its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 3.4% in the fourth quarter, ...

Hunter Associates Investment Management LLC reduced its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 23.6% in the fourth quarter, according to the company in its most recent filing with the ...

Exchange Traded Concepts LLC lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 37.5% during the 4th ...